Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression

Alessia Cimadamore, Silvia Gasparrini, Roberta Mazzucchelli, Andrea Doria, Liang Cheng, Antonio Lopez-Beltran, Matteo Santoni, Marina Scarpelli, Rodolfo Montironi

Research output: Contribution to journalShort survey

11 Scopus citations

Abstract

Long non-coding RNAs (lncRNAs) are a class of RNA with transcripts longer than 200 nucleotides that lack functional open reading frames. They play various roles in human carcinoma, such as dysregulating gene expression in prostate cancer (PCa), which results in cancer initiation, development, and progression. The non-coding RNA SChLAP1 (second chromosome locus associated with prostate-1) is highly expressed in approximately 25% of PCas with higher prevalence in metastatic compared to localized PCa. Its expression is detectable non-invasively in PCa patient urine samples. Experimental data suggest that targeting SChLAP1 may represent a novel therapeutic application in PCa. This contribution focuses on the role of lncRNAs SChLAP1 expression in PCa diagnosis and prognosis.

Original languageEnglish (US)
Article number305
JournalFrontiers in Oncology
Volume7
Issue numberDEC
DOIs
StatePublished - Dec 12 2017

Keywords

  • Lethal prostate cancer
  • Long non-coding RNA
  • Marker of aggressiveness
  • Metastatic prostate cancer
  • Prognostic biomarker
  • Second chromosome locus associated with prostate-1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression'. Together they form a unique fingerprint.

  • Cite this

    Cimadamore, A., Gasparrini, S., Mazzucchelli, R., Doria, A., Cheng, L., Lopez-Beltran, A., Santoni, M., Scarpelli, M., & Montironi, R. (2017). Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression. Frontiers in Oncology, 7(DEC), [305]. https://doi.org/10.3389/fonc.2017.00305